問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Obstetrics & Gynecology

Division of Radiation Therapy

更新時間：2024-06-13

徐國軒HSU, KUO-HSUAN
  • Principal Investigator
  • Clinical Trial Experience (year)

  • vghryan@gmail.com

Recruiting Trial

110Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐國軒

Taichung Veterans General Hospital

Division of Thoracic Medicine

List

159Cases

2015-11-01 - 2025-08-29

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2008-10-01 - 2010-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-01-01 - 2024-11-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-08-01 - 2026-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2023-04-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2018-04-30 - 2020-04-30

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-04-01 - 2022-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2009-04-15 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-09-29 - 2013-12-16

Phase II

A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MM-121(SAR256212)

Participate Sites
6Sites

Terminated6Sites

1 8 9 10 11 12 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB